Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
ImmunoIVD AB
AB
Active
Org 5590180732
Nacka Strand
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2015 · 11 years old
27 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ImmunoIVD AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
86M
64M
43M
21M
0M
2021: 35M
35M
2021
2022: 42M (+20% vs 2021)
42M
+20%
2022
2023: 49M (+17% vs 2022)
49M
+17%
2023
2024: 58M (+18% vs 2023)
58M
+18%
2024
2025: 69M (+19% vs 2024)
69M
+19%
2025
EBITDA
SEK millions
22M
17M
11M
6M
0M
2021: 1M
1M
2021
2022: 10M (+900% vs 2021)
10M
+900%
2022
2023: 8M (-20% vs 2022)
8M
-20%
2023
2024: 17M (+113% vs 2023)
17M
+113%
2024
2025: 18M (+6% vs 2024)
18M
+6%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
68 919
58 270
49 234
42 371
35 308
Staff expenses
−24 188
—
—
—
—
EBITDA
18 211
16 650
8 024
9 576
546
Depreciation & amort.
−1 851
−2 271
−2 244
−2 481
−2 043
EBIT
16 360
14 379
5 780
7 095
−1 497
Net financials
−954
−976
−1 375
−1 536
−1 330
Profit before tax
11 540
13 402
4 405
5 560
−2 827
Tax
−2 396
−2 771
1 543
1 236
−0
Net profit
9 144
10 631
5 948
6 796
−2 827
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
53 674
42 539
32 893
31 240
25 202
Equity
27 125
17 996
8 069
7 111
136
Long-term debt
0
0
0
0
0
Short-term debt
22 684
24 544
24 824
24 129
25 066
Total debt
22 684
24 544
24 824
24 129
25 066
Financial ratios
5-year trend
EBITDA margin
26,4 %
This company
15,8 %
Market median
This company
Market median
67% above market
2021
2025
Equity ratio
50,5 %
This company
38,2 %
Market median
This company
Market median
32% above market
2021
2025
Return on equity
33,7 %
This company
18,4 %
Market median
This company
Market median
83% above market
2021
2025
Net profit margin
13,3 %
This company
8,1 %
Market median
This company
Market median
64% above market
2021
2025
Asset turnover
1,28×
This company
1,12×
Market median
This company
Market median
14% above market
2021
2025
Debt / equity
0,98×
This company
0,62×
Market median
This company
Market median
58% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on ImmunoIVD AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
